Abstract
Many business handle compounds which may have adverse effects upon people but for which no governmental exposure limits exists. There is increasing interest and encouragement in setting ‘in-house’ limits but this is a difficult, imprecise and controversial area. This paper setting out the philosophy and practice of one pharmaceutical company is offered as a contribution to seeking a rational approach to the problem.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of the Society of Occupational Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
